Pancreatic Cancer Research

ResearcherUniversity of Maryland, BaltimoreActive in the last 2 years

Jochen Gaedcke

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6130-5874; OpenAlex author ID A5023489930. Sources: OpenAlex.

Their work

Papers
32 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
124
Papers, trials and grants by year

2012: 1 paper · 2013: 4 papers · 2014: 1 paper · 2015: 2 papers · 2016: 4 papers · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 3 papers · 2021: 2 papers · 2022: 2 papers · 2023: 4 papers · 2024: 4 papers · 2025: 2 papers

Papers 32

  1. KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Co-author DOI 10.1002/1878-0261.13725↗
  2. Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-334374↗
  3. ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer. Co-author DOI 10.1002/ijc.34960↗
  4. LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism. Co-author DOI 10.1093/carcin/bgae011↗
  5. MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. Co-author DOI 10.1093/carcin/bgae025↗
  6. ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. Co-author DOI 10.1093/carcin/bgae056↗
  7. SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2023.113434↗
  8. Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer. Co-author DOI 10.1038/s41698-023-00459-9↗
  9. Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2022-328154↗
  10. Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-22-0916↗
  11. Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer patients. Co-author DOI 10.1093/carcin/bgac092↗
  12. Targeting STAT3 Signaling Facilitates Responsiveness of Pancreatic Cancer Cells to Chemoradiotherapy. Co-author DOI 10.3390/cancers14051301↗
  13. STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-2874↗
  14. Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer. Co-author DOI 10.3390/cells10123463↗
  15. NO• /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer. Co-author DOI 10.1002/ijc.32733↗
  16. CA19-9 for detecting recurrence of pancreatic cancer. Last author DOI 10.1038/s41598-020-57930-x↗
  17. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Co-author DOI 10.1158/0008-5472.can-20-0672↗
  18. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. Co-author DOI 10.1016/j.ebiom.2019.01.037↗
  19. The impact of preoperative biliary stenting in pancreatic cancer: A case-matched study from the German nationwide pancreatic surgery registry (DGAV StuDoQ|Panc… Co-author DOI 10.1016/j.pan.2019.09.007↗
  20. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Co-author DOI 10.1158/0008-5472.can-17-0634↗
  21. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer. Co-author DOI 10.1093/jnci/djv387↗
  22. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Co-author DOI 10.1158/0008-5472.can-15-2841↗
  23. Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-0511↗
  24. Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. Co-author DOI 10.18632/oncotarget.10323↗
  25. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. Co-author DOI 10.1038/ncomms8677↗
  26. Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. Co-author DOI 10.15252/embj.201489574↗
  27. CFTR, SPINK1, PRSS1, and CTRC mutations are not associated with pancreatic cancer in German patients. Co-author DOI 10.1097/mpa.0000000000000166↗
  28. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. First author DOI 10.1002/cncr.27762↗
  29. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pa… Co-author DOI 10.1002/ijc.27736↗
  30. FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-13-0362↗
  31. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-0209↗
  32. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0031507↗

Closest collaborators

The 25 strongest of 124 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael B. Ghadimi · 10 shared papers, 2013–2025 · strength 1.44
  2. Nader N Hanna · 14 shared papers, 2012–2024 · strength 1.39
  3. S. Perwez Hussain · 14 shared papers, 2012–2024 · strength 1.39
  4. Azadeh Azizian · 8 shared papers, 2020–2024 · strength 1.23
  5. Elisabeth Heßmann · 11 shared papers, 2015–2025 · strength 1.14
  6. Yuuki Ohara · 6 shared papers, 2022–2024 · strength 1.03
  7. Volker Ellenrieder · 7 shared papers, 2015–2025 · strength 0.79
  8. Steven A. Johnsen · 7 shared papers, 2016–2025 · strength 0.78
  9. Β. Michael Ghadimi · 12 shared papers, 2012–2022 · strength 0.73
  10. Paloma Moreno · 4 shared papers, 2023–2024 · strength 0.72
  11. Shouhui Yang · 7 shared papers, 2016–2024 · strength 0.71
  12. Xin Wang · 5 shared papers, 2020–2025 · strength 0.65
  13. Ana P. Kutschat · 4 shared papers, 2021–2025 · strength 0.57
  14. Zeynab Najafova · 4 shared papers, 2021–2025 · strength 0.57
  15. S. S. Yang · 3 shared papers, 2024 · strength 0.56
  16. Feda H. Hamdan · 4 shared papers, 2019–2023 · strength 0.46
  17. Amro M. Abdelrahman · 3 shared papers, 2023–2025 · strength 0.45
  18. Mark Joseph Truty · 3 shared papers, 2023–2025 · strength 0.45
  19. H. Richard Alexander · 8 shared papers, 2012–2020 · strength 0.36
  20. Marian Grade · 2 shared papers, 2022–2025 · strength 0.33
  21. Günter Schneider · 2 shared papers, 2022–2025 · strength 0.33
  22. Thomas L. Ekstrom · 2 shared papers, 2023–2025 · strength 0.32
  23. Albrecht Neeße · 4 shared papers, 2015–2021 · strength 0.32
  24. Jens Thomas Siveke · 3 shared papers, 2015–2023 · strength 0.30
  25. Alexander Otto König · 3 shared papers, 2015–2022 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.